Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:AVTE NASDAQ:ENGN NASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$2.70+3.1%$2.67$0.40▼$5.48$45.85M0.27346,117 shs90,846 shsAVTEAerovate Therapeutics$7.49+2.3%$8.64$56.35▼$105.00$77.68M0.9512,438 shs77,779 shsENGNenGene$3.68+3.1%$3.60$2.65▼$11.00$188.07M-0.41103,106 shs29,863 shsIPHAInnate Pharma$2.18+1.9%$1.95$1.29▼$3.51$193.59M0.2212,922 shs5,518 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma0.00%-1.82%-19.40%+123.14%+300.71%AVTEAerovate Therapeutics+2.32%+8.71%-28.73%-13.41%-87.19%ENGNenGene0.00%-3.92%0.00%+24.32%-47.65%IPHAInnate Pharma0.00%+1.40%+20.44%-10.66%+2.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABVCABVC BioPharma0.7897 of 5 stars0.05.00.00.02.00.80.0AVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENGNenGene3.2968 of 5 stars3.55.00.00.01.92.50.6IPHAInnate Pharma2.326 of 5 stars3.75.00.00.00.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 0.00N/AN/AN/AAVTEAerovate Therapeutics 0.00N/AN/AN/AENGNenGene 3.00Buy$23.29532.76% UpsideIPHAInnate Pharma 3.33Buy$11.00404.59% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, ENGN, AVTE, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K89.89N/AN/A$0.06 per share45.00AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AIPHAInnate Pharma$21.77M9.23N/AN/A$0.11 per share19.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$4.90M-$0.13N/A∞N/A-963.46%-29.62%-14.08%8/13/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%8/11/2025 (Estimated)ENGNenGene-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%9/10/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)Latest ABVC, ENGN, AVTE, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTEAerovate Therapeutics-$0.25N/AN/AN/AN/AN/A6/10/2025Q2 2025ENGNenGene-$0.4768-$0.51-$0.0332-$0.51N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.220.22AVTEAerovate TherapeuticsN/A8.788.78ENGNenGene0.0912.6612.66IPHAInnate Pharma2.522.602.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%AVTEAerovate TherapeuticsN/AENGNenGene64.16%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma17.10%AVTEAerovate Therapeutics24.90%ENGNenGene10.40%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3016.98 million14.08 millionNot OptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableENGNenGene3151.10 million45.79 millionN/AIPHAInnate Pharma22092.18 million62.79 millionNot OptionableABVC, ENGN, AVTE, and IPHA HeadlinesRecent News About These CompaniesInnate Pharma (NASDAQ:IPHA) Trading Down 0.5% - Here's WhyAugust 9 at 3:29 AM | marketbeat.comInnate Pharma Announces Its Participation in the BTIG Virtual Biotechnology ConferenceJuly 29, 2025 | businesswire.comInnate Pharma (NASDAQ:IPHA) Trading 1.7% Higher - What's Next?July 17, 2025 | marketbeat.comIPHA Innate Pharma S.A. - Seeking AlphaJuly 2, 2025 | seekingalpha.comInnate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare ConferencesJune 17, 2025 | businesswire.comInnate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) CongressJune 13, 2025 | businesswire.comInnate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare ConferencesMay 27, 2025 | businesswire.comASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibodyMay 23, 2025 | fiercebiotech.comFOutcome of Innate Pharma’s 2025 Annual General MeetingMay 23, 2025 | finance.yahoo.comInnate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis FungoidesMay 23, 2025 | businesswire.comOutcome of Innate Pharma's 2025 Annual General MeetingMay 23, 2025 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2025 Annual MeetingMay 19, 2025 | businesswire.comInnate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 CongressMay 15, 2025 | businesswire.comInnate Pharma S.A. (IPHA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comInnate Pharma Reports First Quarter 2025 Business Update and Financial ResultsMay 13, 2025 | businesswire.comInnate Pharma announces conference call and webcast for Q1 2025 business updateMay 6, 2025 | businesswire.comInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-FApril 30, 2025 | businesswire.comInnate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025April 29, 2025 | tipranks.comInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual MeetingApril 29, 2025 | businesswire.comInnate Pharma price target lowered to $11 from $11.50 at H.C. WainwrightApril 25, 2025 | markets.businessinsider.comInnate Pharma Announces €15M Investment by SanofiApril 24, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, ENGN, AVTE, and IPHA Company DescriptionsABVC BioPharma NASDAQ:ABVC$2.70 +0.08 (+3.05%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.73 +0.03 (+1.11%) As of 08/8/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Aerovate Therapeutics NASDAQ:AVTE$7.49 +0.17 (+2.32%) As of 08/8/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.enGene NASDAQ:ENGN$3.68 +0.11 (+3.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.76 +0.07 (+2.04%) As of 08/8/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Innate Pharma NASDAQ:IPHA$2.18 +0.04 (+1.87%) Closing price 08/8/2025 03:57 PM EasternExtended Trading$2.18 0.00 (0.00%) As of 08/8/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
